Form 4: Bicycle Therapeutics COO Sells Shares for Tax Obligations
Insider Transaction Report
Bicycle Therapeutics' Chief Operating Officer, Alistair Milnes, sold a total of 2,115 ordinary shares across two transactions in early July 2025 to satisfy tax withholding obligations related to restricted stock unit vesting.
Summary
- Alistair Milnes, Chief Operating Officer of Bicycle Therapeutics PLC (BCYC), reported the sale of ordinary shares.
- On July 2, 2025, 1,149 ordinary shares were sold at a weighted average price of $7.09 per share, with prices ranging from $7.09 to $7.14.
- On July 3, 2025, an additional 966 ordinary shares were sold at a weighted average price of $7.44 per share, with prices ranging from $7.405 to $7.44.
- These sales were non-discretionary 'sell to cover' transactions, mandated by the reporting person's award agreement to satisfy statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units.
- Following these transactions, Alistair Milnes directly beneficially owns 95,502 ordinary shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document reports a routine, non-discretionary 'sell to cover' transaction for tax purposes, which does not indicate a change in management's confidence or the company's operational performance.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategy.
Management Comments
- The sale of shares was mandated by the Reporting Person's award agreement, requiring the satisfaction of minimum statutory tax withholding obligations to be funded by a 'sell to cover' transaction.
- The sale does not represent a discretionary sale by the Reporting Person.
Industry Context
This Form 4 filing details a routine insider transaction, specifically a 'sell to cover' event for tax purposes related to restricted stock unit vesting. Such transactions are common across all industries, including biotechnology, and do not typically reflect broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Minimal impact, as the sale is a routine, non-discretionary event for tax purposes and does not signal a change in management's outlook or a significant dilution.
Key Dates
| Date | Description |
|---|---|
| 07/02/2025 | First transaction date: Sale of 1,149 ordinary shares by Alistair Milnes. |
| 07/03/2025 | Second transaction date: Sale of 966 ordinary shares by Alistair Milnes. |
| 07/07/2025 | Date the Form 4 was signed and filed. |
Recommendation
holdKeywords
Bicycle Therapeutics, BCYC, Form 4, Insider Transaction, Share Sale, Restricted Stock Units, Tax Withholding, Alistair Milnes, Chief Operating Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.